Oral breast cancer vaccine may offer new prevention tool

Jason Steel, PhD, is a lung cancer researcher with the UC Cancer Institute.

(Medical Xpress)—A new oral vaccine that produces a novel two-pronged immune system attack on cancer cells could be effective in preventing breast cancer recurrence, according to findings from a collaborative research team from the University of Cincinnati (UC) Cancer Institute and the National Institutes of Health (NIH).

This is the first scientific report of using oral delivery of a unique virus—known as recombinant adeno-associated virus (AAV)—as a cancer vaccine. First author and UC College of Medicine research assistant professor Jason Steel, PhD, and colleagues reported their findings in the Jan. 8. 2013, issue of Molecular Therapy, the journal of the American Society of Gene and Cell Therapy.

Although other oral breast vaccines have been studied in animal models, these vaccines raised human safety concerns because they used bacteria known to have potential harm to human health.

In conjunction with NIH researchers, the UC team sought to develop a vaccine using AAV, a virus that has been shown to have minimal negative effects on human health and is currently being investigated as a gene therapy platform for treating inherited genetic disorders.

"AAV is special because the virus survives the stomach," explains Steel. "Normally, you introduce a virus by mouth and it is broken down in the stomach. This virus is resistant to breakdown, which opened up the possibility of administering it orally as a cancer vaccine."

In this preclinical , the UC team tested two strains of AAV—one that was able to escape the stomach and move into the bloodstream, the other staying in the stomach. Studies were conducted to show both short-term and long-term impact on the reduction of breast cancer tumors. The team also evaluated which delivery method was more effective—oral versus the traditional intramuscular injection.

"The strain that remained in the stomach was more effective at preventing breast cancer tumors than the strain that traveled systemically—100 percent of study subjects had no tumors for over a year following the treatment," says Steel. "Additionally, we showed that (versus intramuscular injection) was more effective, resulting in a stronger immune response with greater than a 100 percent increase in anti-tumor antibodies at the lower doses and increased survival."

Researchers say this AAV-based oral holds potential as a human breast cancer prevention tool in individuals who have been treated for a certain type of or those deemed at increased risk for the disease.

"We have done similar studies with different virus strains that have produced an antibody response," adds Steel. "With this virus, we get both an antibody and a tumor-killer T-cell response. By combining the two mechanisms of action in one vaccine, we are creating a two-pronged immune system attack on the that appears to be more effective."

The UC team expects to begin testing the AAV-based for prevention of other cancers, including lung cancer, in 2013.

Related Stories

Tattooing improves response to DNA vaccine

Feb 07, 2008

A tattoo can be more than just a fashion statement – it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.

Recommended for you

Why we should vaccinate boys against HPV as well as girls

1 hour ago

Gillian Prue, from the School of Nursing and Midwifery at Queen's University of Belfast, says that the human papillomavirus (HPV) infection is common in men and can lead to genital warts and the development of some head and ...

Generation of tanners see spike in deadly melanoma

13 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

13 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

pokerdice1
not rated yet Jan 18, 2013
This is really promising...